Overview
Learn about bispecific antibodies as an innovative immunotherapy treatment option for patients with relapsed or refractory multiple myeloma in this 23-minute educational video. Explore the mechanisms, applications, and potential benefits of this cutting-edge therapy as Dr. Omar Nadeem provides expert insights into how these specialized antibodies function in treating multiple myeloma. Gain valuable understanding of the latest advancements in cancer treatment from Dana-Farber Cancer Institute's Multiple Myeloma Program, offering hope for patients who have not responded to conventional therapies.
Syllabus
Bispecific Antibodies in Multiple Myeloma | Dana-Farber Cancer Institute
Taught by
Dana-Farber Cancer Institute